Merus to Present at the Leerink Partners 6th Annual Global Healthcare Conference
UTRECHT, The Netherlands, 2017-02-09 13:00 CET (GLOBE NEWSWIRE) --
Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will participate at the Leerink Partners 6thAnnual Global Healthcare Conference on Thursday, February 16, 2017 at 3:00 p.m. ET at the Lotte New York Palace Hotel.
A live webcast of the presentation will be available on the Investors page of the Company's website,http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1/ 2 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
+1 973 361 1546
+1 646 368 8014
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Bombardier Transportation20.6.2018 11:54 | pressemeddelelse
Bombardier's Chinese Joint Venture Wins Contract to Provide an INNOVIA Automated People Mover System to Shenzhen Airport
Erytech Pharma S.A.20.6.2018 07:32 | pressemeddelelse
ERYTECH to Present at JMP Securities Life Science Conference
Crown Bioscience Inc.19.6.2018 14:01 | pressemeddelelse
CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents
Glatfelter19.6.2018 13:45 | pressemeddelelse
Glatfelter to Acquire Georgia-Pacific's European Nonwovens Business for $185 Million
Lithium Werks19.6.2018 09:02 | pressemeddelelse
Lithium Werks and Endrich agree pan-Asian battery distribution deal
PubMatic, Inc.19.6.2018 09:02 | pressemeddelelse
PubMatic Launches PubMatic Cloud to Evolve the SSP Business Model
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum